UMC Utrecht spinout Gadeta has partnered cancer drug developer Kite to drive development of its T-cell therapy, allowing Kite to purchase equity from Gadeta's existing shareholders.

Kite, a cancer drug subsidiary of biopharmaceutical firm Gilead Sciences, has made a secondary investment in Gadeta, a Netherlands-based immuno-oncology spinout from University Medical Center Utrecht. The deal forms part of a strategic partnership to harness the gamma delta T-cell receptor for treatments targeting various cancers. Kite will provide Gadeta with funding for R&D and…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.